載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.7601
−US$0.0099 · -1.29%
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
前收盤價
US$0.7601
−US$0.0099 · -1.29%
盤中時間採用ET。市場資料可能有所延遲。
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
日內區間
目前US$0.7601
52週區間
目前US$0.7601
盤中時間採用ET。市場資料可能有所延遲。
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
日內區間
目前US$0.7601
52週區間
目前US$0.7601
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 38.9萬 USD | — | — | — |
| 毛利 | — | −38.9萬 USD | — | — | — |
| 研究與開發 | 1260.6萬 USD | 2847.6萬 USD | 1749.8萬 USD | 2252.7萬 USD | 1716.6萬 USD |
| 銷售、一般及管理費用 | 1396.9萬 USD | 1355萬 USD | 1165.9萬 USD | 1211.3萬 USD | 982萬 USD |
| 營業費用 | 2657.5萬 USD | 4163.7萬 USD | 2915.7萬 USD | 3464萬 USD | 2698.6萬 USD |
| 利息收入 | 52萬 USD | 149.9萬 USD | 111.5萬 USD | 54.9萬 USD | 1282 USD |
| 利息支出 | 20.7萬 USD | 131.6萬 USD | 144.9萬 USD | 161.8萬 USD | 128.2萬 USD |
| 折舊和攤銷 | 26.6萬 USD | 38.9萬 USD | 38.1萬 USD | 63.8萬 USD | 37.4萬 USD |
| 營業利益 | −2657.5萬 USD | −4202.6萬 USD | −2915.7萬 USD | −3464萬 USD | −2698.6萬 USD |
| 淨利 | −2626.2萬 USD | −4184.3萬 USD | −2949.1萬 USD | −3570.9萬 USD | −2830.2萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年4月9日 | 1:13 | — | — |
股票分割 | 2021年6月28日 | 1:15 | — | — |
股票分割 | 2018年12月10日 | 1:15 | — | — |
已生效 2025年4月9日
1:13
已生效 2021年6月28日
1:15
已生效 2018年12月10日
1:15
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
